Helena A. Yu

1. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
   2023/12/10 by Helena A. Yu, Yasushi Goto, Hidetoshi Hayashi +26 · 1 citation
2. Osimertinib Plus Gefitinib in Patients with <i>EGFR</i> -Mutated Advanced Non-Small Cell Lung Cancer and <i>EGFR</i> (C797X) Mutation Following First-Line Osimertinib: ORCHARD
   2026/07/13 by Sarah B. Goldberg, Myung‐Ju Ahn, Christina S. Baik +19 · 1 voice
   Medicine · #Lung Cancer Treatments and Mutations #Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis #Lung Cancer Diagnosis and Treatment